On October 28, 2026, InstallatørGruppen A/S (”InstallatørGruppen”) launched a share buyback program. Under this program, which will run from November 2, 2026, through March 31, 2027, InstallatørGruppen intends to repurchase shares for a total maximum consideration of up to DKK 25 million.

The share buyback program has been initiated in accordance with the provisions of the EU Commission Regulation No. 596/2014 of April 16, 2014, on market abuse — commonly known as the Market Abuse Regulation. This regulation serves to protect the boards and executive management of publicly listed companies from violating insider trading laws in connection with share repurchase activities.

The following transactions have been carried out under this program:

  Number of shares Average purchase price (DKK per share) Total amount (DKK)
Accumulated as per previous announcement 169,500 12.80 2,169,667
November 6, 2026 46,850 12.77 598,143
November 9, 2026 49,500 12.97 642,198
November 10, 2026 50,700 13.12 665,250
November 11, 2026 55,700 13.41 746,692
November 12, 2026 59,000 13.43 792,447
Total accumulated 431,250 13.02 5,614,397

The share repurchase transactions were carried out by InstallatørGruppen’s financial advisor, ABG Sundal Collier.

As at the date of this announcement, InstallatørGruppen holds 2,562,143 treasury shares, corresponding to 0.85% of the total number of issued shares, which amounts to 300,503,757.

Contact details

Head of ESG & Communications
Morten Reedtz Kjellev
+45 2921 6999
mk@i-g.dk

Head of M&A and Investor Relations
Maximillian Hjorth Beste
+45 2899 2846
mhb@i-g.dk

About InstallatørGruppen

InstallatørGruppen is a leading provider of multi-disciplinary technical installation services in Denmark and Switzerland. The Group comprises independent companies with a strong local presence and in-depth technical expertise. The companies within the Group offer solutions in the fields of plumbing, heating, ventilation/air conditioning, refrigeration and electrical systems, as well as in selected specialist areas such as sprinkler systems, energy optimisation, building automation, fibre-optic infrastructure and solar panel installations. The Group’s aim is to be a preferred partner for its customers in implementing the energy transition. InstallatørGruppen is listed on Nasdaq Copenhagen.

Attachment

Tembo KOVA is a five-seat dual-cab electric pickup truck with a motor on each axle, configured for demanding off-road and rugged on-road B2B fleet applications

Tembo KOVA will be available in Australia, New Zealand, the Philippines and Nepal

88 kWh CATL LFP battery with OEM partner manufacturer-stated range of up to 510 km (CLTC) and 460 km (WLTP)

Payload of up to 1,200 kg, braked towing capacity of up to 3,000 kg, gross vehicle mass (GVM) of 3,520 kg and gross combination mass (GCM) of 6,520 kg

Peak combined output of up to 200 kW and 485 Nm; DC fast charging from 20% to 80% in approximately 45 minutes through a CCS port

Tembo KOVA sits alongside the Tembo Tusker and Tembo EUV E-Power (E-Conversion) models, giving fleet customers the choice of a new electric vehicle or electrification of an existing one

LONDON, UK / EINDHOVEN, NETHERLANDS, Nov. 13, 2026 (GLOBE NEWSWIRE) — VivoPower PLC (Nasdaq: VIVO) (“VivoPower” or the “Company”), a leading B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced that its electric vehicle subsidiary, Tembo e-LV B.V. (“Tembo”), has launched Tembo KOVA, a new all-electric four-wheel-drive (4WD) truck. Tembo KOVA is intended for fleet customers seeking a practical electric utility pickup for demanding off-road and on-road applications, including mining, agriculture, energy, construction, infrastructure, government and safari tourism.

KOVA stands for Kinetic Off-road Vehicle Architecture, Tembo’s dual-motor electric 4WD pickup offering configured for demanding off-road terrain and rugged on-road fleet duty.

Kevin Chin, Executive Chairman and CEO, said: “Most of the fleet operator demand we see across our key markets is for 4WD utility pickup trucks, based on our in-the-field customer business development activities across multiple industries. The introduction of Tembo KOVA adds a 4WD electric utility pickup well suited to demanding off-road and rugged on-road fleet use cases, positioning Tembo to address growing customer interest driven by high and volatile diesel prices in our key markets. We are pleased to be able to offer the Tembo KOVA to fleet operators in Australia, New Zealand, the Philippines and Nepal. In turn, adding a dedicated 4WD pickup to our lineup is expected to help Tembo compete in the fast-growing electric 4WD pickup segment and support its path toward profitable growth.”

Addressable Markets

Tembo estimates that approximately 223,000 new four-wheel-drive (4WD) pickup trucks will be sold in 2026 across the four markets in which Tembo KOVA will be offered, with an estimated annual market value of approximately US$9 billion covering all powertrains, at current retail prices; these estimates are not the battery-electric market or a forecast of Tembo sales. Australia is the largest of these markets, accounting for approximately 83% of estimated 2026 units and 86% of estimated value.

Electrification of the 4WD pickup segment in these markets is increasing off a low base, with battery-electric 4WD pickups effectively absent in 2024 as initial offerings have only recently been introduced. Based on Company estimates derived from industry registration, import and model-level data, battery-electric 4WD pickup sales across the four launch markets are estimated to have grown from approximately 100 units in 2025 to an annualized pace of approximately 1,200 units in 2026. This still accounts for less than 1% of new 4WD pickup sales. In the table below, the 2026E EV and hybrid column is broader than battery-electric models and also includes plug-in hybrid and full-hybrid 4WD pickups.

The table below sets out Tembo’s estimates of new pickup truck sales in each launch country. Four-wheel-drive models account for approximately 80% of the approximately 278,000 new pickups estimated to be sold across the four markets in 2026. The 4WD share is highest in Australia and New Zealand, at approximately 89% in both markets, and lower in the Philippines and Nepal, at approximately 32% and 25% respectively.

Estimated 4WD Pickup Markets in Tembo KOVA Launch Countries1

Market All new pickups, 2026E (units)2 New 4WD EV and hybrid pickups, 2026E (units)3 New 4WD pickups, 2026E (units)3 Est. market value p.a., 2026E (local currency)4 Est. market value p.a., 2026E (US$)5
Australia ~209,000 ~24,800 ~186,400 A$11.2 billion US$7.7 billion
New Zealand ~27,000 ~2,950 ~24,000 NZ$1.48 billion US$0.8 billion
Philippines ~38,000 ~2,300 ~12,000 PHP 26.8 billion US$0.4 billion
Nepal6 ~4,180 ~50 ~1,030 NPR 6.8 billion US$0.1 billion
Total ~278,000 ~30,100 ~223,400 n/a ~US$9.0 billion


1
“All new pickups” covers every new pickup truck sold, both two-wheel drive (4×2) and four-wheel drive (4×4), across all powertrains. “New 4WD pickups” is the four-wheel-drive subset only, which is the segment in which Tembo KOVA competes. Two-wheel-drive pickups, which make up most of the pickup market in the Philippines and Nepal, are excluded from the 4WD columns and from the estimated market values.

2 Company estimates of all new pickup trucks, two-wheel drive and four-wheel drive. Australia: Federal Chamber of Automotive Industries (FCAI) VFACTS 4×2 and 4×4 pickup/cab-chassis segments under A$100,000, with 2026E based on annualized January to October 2026 VFACTS 4×2 and 4×4 sales; excludes approximately 9,000 US full-size pickups a year. New Zealand: estimated from reported 4×2 and 4×4 registrations. Philippines: based on industry association reporting (excluding the Toyota Tamaraw utility vehicle) without the non-reporting-distributor adjustment included in the 4WD estimate in note 3; the implied Philippine 4WD share therefore reflects different coverage bases. Nepal: all pickup imports, including single cab and electric models, for fiscal year 2082/83.

3 Company estimates. Australia: 2026E based on FCAI VFACTS January to October 2026 4×4 pickup sales plus November to December 2025 sales adjusted for the year-to-date change. New Zealand and the Philippines: estimated from industry light commercial vehicle data and model-level 4×4 shares, as no official 4WD pickup series is published. Excludes US full-size pickups. EV and hybrid 4WD pickups (a subset of New 4WD pickups) include battery-electric, plug-in hybrid (including externally chargeable range-extended) and full-hybrid 4WD pickups, and exclude 48-volt mild hybrids and two-wheel-drive models. These are rounded Company estimates derived from available sales, registration and import data and assumed model and drivetrain mixes, within estimated ranges of approximately 23,900 to 26,100 units for Australia, 2,790 to 3,115 for New Zealand, 1,400 to 3,400 for the Philippines and 30 to 85 for Nepal. Nepal uses fiscal year 2082/83 imports as a proxy for sales. Philippine 4WD pickup estimates include an adjustment of approximately 2,000 units for distributors that do not report to the industry association, and Philippine EV and hybrid estimates are particularly uncertain.

4 Units multiplied by estimated average retail prices including local taxes: Australia A$60,300 (list price before on-road costs); New Zealand NZ$61,500; Philippines PHP 2.23 million; Nepal NPR 6.6 million. Figures represent total retail spend across all powertrains and are not a forecast of Tembo KOVA sales or revenue.

5 Converted at exchange rates on November 13, 2026: A$1 = US$0.6805; NZ$1 = US$0.5546; US$1 = PHP 63.56; US$1 = NPR 150.78.

6 Nepal: estimated from Department of Customs pickup import data and an assumed 4×4 share. 2026E is fiscal year 2082/83 (mid-July 2025 to mid-July 2026). This period is not directly comparable with the calendar-year estimates for the other markets.

Expanding Fleet Electrification Options

Tembo KOVA joins the Tembo Tusker (100% Electric) and Tembo EUV E-Power (E-Conversion) models, giving fleet operators a broader choice of electric utility solutions. Depending on fleet replacement cycles, operating conditions and total cost of ownership, Tembo can support customers considering either a new electric vehicle or the electrification of an existing vehicle.

Tembo’s fleet engagement approach considers duty cycles, load requirements, charging needs and potential operational savings. Aftersales support, parts availability and application-specific requirements form part of those customer discussions.

Vehicle Overview and Key Specifications

The five-seat dual cab combines an 88 kWh lithium iron phosphate (LFP) battery from CATL with a dual-motor 4WD drivetrain, for a manufacturer-stated range of up to 510 km on the CLTC laboratory test cycle and 460 km on the WLTP cycle. The front motor delivers up to 70 kW and 165 Nm, and the rear motor delivers up to 130 kW and 320 Nm. Peak combined output is up to 200 kW and 485 Nm of torque.

Tembo KOVA has front coil springs, rear leaf springs, four-wheel disc brakes and a manufacturer-stated maximum payload of up to 1,200 kg and manufacturer-stated braked towing capacity of up to 3 metric tons (3,000 kg). AC and DC charging are supported through a CCS port, with DC charging from 20% to 80% in approximately 45 minutes. Manufacturer-listed safety equipment includes autonomous emergency braking (AEB), stability control, ABS with electronic brake-force distribution, hill hold, an electronic parking brake and front airbags. The cabin features a 12.3-inch display with Apple CarPlay and Android Auto. CATL, Apple CarPlay and Android Auto are trademarks of their respective owners.

Tembo KOVA: Key Specifications

Drivetrain Four-wheel drive; front and rear motors
Battery 88 kWh LFP, CATL
Peak motor power Front 70 kW; rear 130 kW
Peak motor torque Front 165 Nm; rear 320 Nm
Peak combined output 200 kW; 485 Nm
Range Up to 510 km (CLTC) and 460 km (WLTP); laboratory cycles, manufacturer-stated
DC charging (20% to 80%) Approximately 45 minutes, CCS
Towing capacity Up to 3 metric tons (3,000 kg), braked (within GCM)
Payload Up to 1,200 kg (manufacturer-stated; reduced by occupants, options and tongue weight)
GVM and GCM 3,520 kg and 6,520 kg respectively
Curb weight 2,180 kg
Dimensions (L × W × H) 5,624 × 1,920 × 1,865 mm
Wheelbase 3,513 mm
Ground clearance 200 mm
Tray (dual cab) 1,810 × 1,620 × 515 mm
Seating 5
Top speed 120 km/h


Note: Specifications are manufacturer-stated figures for the reference configuration and remain subject to change, local homologation and final market configuration. Maximum payload and towing cannot necessarily be achieved simultaneously. CLTC range, which typically yields higher figures than WLTP, and DC charging times are laboratory or test figures; actual range and charging speeds vary with load, towing, terrain, weather and charger output.

About VivoPower

Originally founded in 2014 and listed on Nasdaq since 2016, VivoPower is an award-winning B Corporation with data center and powered land infrastructure across Norway, Finland, and the United Arab Emirates. The Company’s mission is to be the independent, trusted partner for sovereign nations that develop and operate sustainable data center infrastructure, ensuring sovereign control over power, data, and national intelligence. In doing so, VivoPower helps sovereign nations bridge the gap between their energy assets and their AI ambitions by providing the Power-to-X infrastructure necessary to build and control their own domestic intelligence hubs.

About Tembo

Tembo provides electric utility vehicle solutions for ruggedized off-road, on-road and customized fleet applications across sectors including mining, agriculture, energy, construction, infrastructure, government and safari tourism. Its portfolio includes new electric utility vehicles and conversion solutions designed to help fleet owners evaluate electrification opportunities and optimize asset utilization. Tembo is a subsidiary of VivoPower.

Forward-Looking Statements

This communication includes certain statements that may constitute “forward-looking statements” for purposes of the U.S. federal securities laws. Forward-looking statements include, but are not limited to, statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about the specifications, performance, pricing and availability of Tembo KOVA, anticipated interest from customers and fleet operators, the expansion of Tembo’s fleet electrification portfolio, estimates of the size, value and growth of the markets for new 4WD pickup trucks and battery-electric 4WD pickup trucks in Australia, New Zealand, the Philippines and Nepal, or the benefits of the events or transactions described in this communication. These statements are based on VivoPower’s management’s current expectations or beliefs and are subject to risk, uncertainty, and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive and/or regulatory factors, and other risks and uncertainties affecting the operation of VivoPower’s business. These risks, uncertainties and contingencies include changes in business conditions, fluctuations in customer demand, changes in accounting interpretations, management of rapid growth, intensity of competition from other providers of products and services, changes in general economic conditions, geopolitical events and regulatory changes, and other factors set forth in VivoPower’s filings with the United States Securities and Exchange Commission. Specifically in relation to Tembo KOVA, vehicle specifications and performance figures are stated figures that may be subject to change, range figures are based on the CLTC and WLTP laboratory test cycles and actual range will vary, and the timing, locations, pricing and ordering arrangements for the vehicle have not yet been finalized. Commercial availability in each market is subject to local vehicle homologation and regulatory approvals, with market-specific specifications, pricing, ordering arrangements and delivery timing to be confirmed. Market size, market value and electric vehicle sales figures are Company estimates derived from third-party industry and customs data, modeled assumptions, average retail prices and exchange rates as of November 13, 2026; they are not forecasts of Tembo KOVA sales or revenue, and actual market volumes, prices and growth may differ materially. Additional risks include reliance on third-party vehicle and battery suppliers; delays in or failure to obtain market-specific homologation and other approvals; changes to specifications following validation or customer trials; supply, logistics, warranty, servicing and parts constraints; charging availability; changes in vehicle taxes, incentives and energy prices; and failure to convert customer interest into orders, deliveries and profitable sales. Market estimates involve classification, reporting-period, pricing and exchange-rate assumptions, and historical figures are not forward-looking statements merely because they are described as estimates. The information set forth herein should be read in light of such risks. VivoPower is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements whether as a result of new information, future events, changes in assumptions or otherwise, except as required by applicable law.

Contact

Shareholder Inquiries
media@vivopower.com

MIAMI, Nov. 13, 2026 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the pricing of its previously announced underwritten public offering of (i) 7,342,308 shares of its common stock, (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase 50,350,000 shares of its common stock, and (iii) accompanying common warrants to purchase 43,269,231 shares of its common stock (or pre-funded warrants in lieu thereof). All securities in the offering are being offered by InspireMD.

In addition, the Company granted the underwriters a 30-day option to purchase additional 8,653,846 shares of the Company’s common stock and/or 8,653,846 pre-funded warrants and/or additional common stock warrants to purchase 6,490,384 shares of common stock (or pre-funded warrants in lieu thereof) (or any combination thereof), representing 15% of the total number of shares of common stock and pre-funded warrants sold in the offering, solely to cover over-allotments, if any.

The offering is expected to close on or about November 16, 2026, subject to satisfaction of customary closing conditions.

Lake Street Capital Markets is acting as the sole book runner for the offering.

InspireMD intends to use the net proceeds from the offering, if any, for research and development, sales and marketing, working capital and other general corporate purposes.

The securities are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-286309) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 1, 2025, and declared effective by the SEC on April 10, 2025. A preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC on November 12, 2026. Copies of the final prospectus supplement and accompanying base prospectus will be filed with the SEC and, when available, may be obtained free of charge at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying base prospectus relating to the offering may be obtained from Lake Street Capital Markets, LLC at 121 South Eighth Street, Suite 1000, Minneapolis, MN 55402, or e-mail at prospectus@lakestreetcm.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.

Forward-looking Statements

This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. These forward-looking statements include, but are not limited to, statements regarding the closing of the offering and the anticipated use of proceeds.

In particular, forward-looking statements in this press release include the Company’s expectations regarding the public offering, including its anticipated completion, and the intended use of proceeds from the offering. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.

Such risks and uncertainties include, without limitation, risks associated with the public offering, including market conditions, the possibility that the offering may not be completed on the anticipated terms or at all, and the Company’s ability to deploy any proceeds from the offering as intended; risks and uncertainties associated with the voluntary U.S. recall of the CGuard Prime 135 cm delivery system, including current and future costs associated with the recall, including refunds or inventory write-off costs and other remediation costs, loss of sales and customers due to the recall or otherwise, our ability to effectively implement enhancements to CGuard Prime 135 cm delivery system, potential actions by regulators or other governmental entities associated with the recall, potential claims and lawsuits by customers and patients, including class action product liability lawsuits, other operational impacts and consequences of the recall, such as business disruption and distraction of management and other key employees; the Company’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of its liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; the Company’s need to raise additional capital to meet its business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute our stockholders’ ownership interests; the clinical development, commercialization and market acceptance of the Company’s products; whether the clinical trial results for the Company’s products will be predictive of real-world results; an inability to secure and maintain regulatory approvals for the sale of the Company’s products; negative clinical trial results or lengthy product delays in key markets; the Company’s ability to maintain compliance with the Nasdaq listing standards; the Company’s ability to generate significant revenues from its products; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays in the ongoing commercial launch of its products; the Company’s dependence on a single manufacturing facility and its ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from the Company’s current and planned clinical trials may not be sufficient to demonstrate that its technology is an attractive alternative to other procedures and products; intense competition in the Company’s industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than it does; entry of new competitors and products and potential technological obsolescence of the Company’s products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with the Company’s research and products and potential product liability claims; product malfunctions; price increases for supplies and components; whether access to the Company’s products is achieved in a commercially viable manner and whether its products receive adequate reimbursement by governmental and other third-party payers; the Company’s efforts to successfully obtain and maintain intellectual property protection covering its products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that the Company conducts business in multiple foreign jurisdictions, exposing it to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; security, political and economic instability in the Middle East that could harm the Company’s business, including due to the current security situation in Israel; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; and changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements and the impact of such policies on the Company, its customers and suppliers, and the global economic environment.

More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:
Jeff Warren
LifeSci Advisors
jwarren@lifesciadvisors.com
investor-relations@inspiremd.com

Building on Nanox.AI’s existing deployment in Athens, the agreement supports commercial expansion in Greece through Medworks‘ established market presence.

PETACH TIKVA, Israel, Nov. 13, 2026 (GLOBE NEWSWIRE) — Nanox Imaging Ltd. (“Nanox” or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that it has entered into a non-exclusive distribution agreement with Medworks LTD (“Medworks”) to support the commercial expansion of Nanox.AI’s HealthOST solution in Greece.

Under the agreement, Medworks has been appointed as a non-exclusive reseller of HealthOST, Nanox.AI’s FDA-cleared and CE-marked AI-based bone solution, in Greece, leveraging its established presence and experience serving healthcare providers across the country. The agreement initially focuses on HealthOST and establishes a commercial relationship through which the companies may explore broader collaboration in the future. Medworks has experience in diagnostic imaging and other medical technologies and provides sales, technical support, applications and customer service capabilities in the Greek market. Medworks’ published company profile describes experience with medical imaging technologies including ultrasound, CT, MRI, X-ray and mammography equipment, as well as cardiology equipment.

The agreement builds on Nanox.AI’s existing presence in Greece and is intended to support the Company’s continued commercial expansion in the Greek market.

“Our agreement with Medworks represents an important step in expanding the commercial reach of Nanox.AI,” said Erez Meltzer, Chief Executive Officer of Nanox. “Medworks’ established presence and experience in the Greek healthcare market will support our efforts to expand access to Nanox.AI and strengthen our presence in Greece.”

“We are pleased to partner with Nanox and introduce Nanox.AI to healthcare providers across Greece,” said Tassos Zachos, Managing Director at Medworks LTD. “By combining Nanox’s AI-powered technology with our experience and relationships in the Greek healthcare market, we look forward to supporting its adoption across the country.”

About Medworks
Medworks LTD is a Greece-based medical technology company supplying and supporting medical imaging, cardiology and other medical equipment. Founded in 2009, the company has experience in the trade and support of high-technology medical systems and operates dedicated customer service, technical support, applications and sales departments. MEDWORKS Company Profile.

About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.

Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.

Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.

The Nanox ecosystem includes Nanox.ARC X, a multi-source digital tomosynthesis system designed to make advanced 3D imaging accessible in more clinical settings; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provides access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.

The Nanox.ARC X was selected as one of TIME’s Best Inventions of 2026.

By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit https://www.nanox.vision.

About Nanox.AI

Nanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox.AI solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI, Nanox.AI helps clinicians extract valuable and actionable clinical insights from medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit www.nanox.vision/ai.

Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of Nanox’s liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; (iv) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (v) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (vi) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vii) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (viii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (ix) Nanox’s ability to conduct business globally; (x) changes in global, political, economic, business, competitive, market and regulatory forces; (xi) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xii) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xiii) potential litigation associated with our transactions.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.

Contacts

Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com

Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW

CALGARY, Alberta, Nov. 13, 2026 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (the “Corporation” or “High Arctic”) released its third quarter 2026 financial and operating results. The unaudited condensed interim consolidated financial statements (the “Financial Statements”) and management discussion & analysis (“MD&A”) for the three and nine months ended September 30, 2026 will be available on SEDAR+ at www.sedarplus.ca, and on High Arctic’s website at www.haes.ca.

All amounts are denominated in thousands of Canadian dollars (“CAD”), unless otherwise indicated.

In the following disclosure, the three months ended September 30, 2026 may be referred to as the “quarter” or “Q3 2026” and the comparative three months ended September 30, 2025 may be referred to as “Q3 2025”. References to other quarters may be presented as “QX 20XX” with X/XX being the quarter/year to which the commentary relates. Additionally, the nine months ended September 30, 2026 may be referred to as “YTD” or “YTD-2026”. References to other nine-month periods ended September 30 may be presented as “YTD-20XX” with XX being the year to which the nine-month period ended September 30 commentary relates.

Lonn Bate, Interim Chief Executive Officer commented:

“High Arctic delivered excellent financial and operational performance in the third quarter of 2026, reflecting strong customer activity and disciplined execution by our Rental Services business. Revenue increased 60% quarter over quarter to $4.7 million, Adjusted EBITDA increased to $1.4 million, representing 31% of revenue, and net income surpassed $1.0 million in the quarter. These excellent results were achieved with a significant effort from our valued staff who consistently delivered quality service while meeting our high level of safety standards for our customers.

“Team Snubbing also delivered consistent operational performance during the quarter. Steady customer demand in Alaska, continued North Slope activity and developing opportunities in Canada supported a 21% increase in Team’s quarterly revenue, while Team made some meaningful investments in relation to new work awarded in the quarter that will strengthen its platform for future growth.

“The strong demand for our service offerings witnessed in Q3 2026 has continued into the fourth quarter of 2026, setting High Arctic up for a strong exit to what has been a busy year.”

Outlook

High Arctic’s business is driven by its customers’ decisions to drill new oil and natural gas wells combined with subsequent activity to complete these wells for production. This drilling and completion activity is tied to expectations for commodity prices and pipeline egress to access markets. As such, the financial and operational performance of High Arctic’s business and the non-operated equity investment in Team Snubbing are highly dependent on these customer factors, in combination with fundamentals associated with both drilling and well completions in the WCSB and in the US state of Alaska.

In the WCSB, High Arctic rental equipment and service operations are currently experiencing a high level of customer demand in central Alberta as certain customers accelerate their capital spending to drill, complete and tie-in more of their Duvernay wells. This work is in close proximity to High Arctic’s primary operations centre. In terms of capital expenditure levels, High Arctic made some opportunistic expenditures in the summer of 2026 to secure needed equipment to deliver the services our customers were requesting of us. For 2027 High Arctic is planning to make additional strategic capital expenditures and headcount additions to both increase the service offerings to our customers and to ensure the quality and timeliness of service delivery we are known for is not compromised.

For High Arctic’s non-operated interest in Team Snubbing, expectations are that operational execution and the additional work has built positive momentum in the business. While the WCSB continues to be challenging in terms of delayed natural gas well completions, Team added a new application for its services in Canada, focused on oil production, and in Alaska has seen continued oil well workover opportunities trend higher. High Arctic expects Team Snubbing to continue to build its customer relationships in Alaska and end the year in a favourable position with three rig packages marketed and labour contract opportunities.

While global economic and geopolitical uncertainty persists and in many respects is escalating, Canada’s energy industry has opportunities for future growth through new pipeline egress to overseas and USA markets. Recent energy infrastructure initiatives to expand throughput of existing pipelines and build new capacity to access tidewaters are developments highlighting a mandate at the federal level for Canada to become a global energy superpower. These initiatives include the announcement of both the West Coast Oil Pipeline from Alberta to the B.C. coast and the Northern Shield Energy Corridor, the US approval of the Bridger Pipeline Expansion, completion of the Trans Mountain pipeline system expansion in 2024, and the output ramp-up of West coast LNG exports in 2025, all of which are positive developments supporting improved long-term fundamentals for High Arctic’s business in the upstream energy services sector.

In summary, the Corporation’s strategic objectives carry forward priorities and accomplishments from a busy 2026. They focus on safe and value based operational execution for customers, cost control, and equipment offerings to enable lasting market opportunities to drive organic growth and enhanced shareholder value.

2026 Strategic Objectives

  • Relentless focus on safety excellence and quality service delivery;
  • Actively manage direct operating costs and general and administrative expenses.
  • Steward capital and liquidity to preserve balance sheet strength and financial flexibility; and
  • Organically grow our core businesses through selective and opportunistic investments;
  • Seek accretive acquisitions in Canada to drive shareholder value;

High Arctic is on track to meet or exceed its 2026 strategic objectives. The Corporation maintained its strong safety performance, continuing to operate without a lost-time incident, while strengthening customer relationships through consistent operational execution and quality service delivery. Selective growth expenditures in specialty equipment supported a record number of customer well completions and contributed to a 36% increase in Rental Services revenue for the first nine months of 2026. This growth translated into improved financial performance, with increased YTD net income and adjusted EBITDA when compared to 2025. At the same time, disciplined capital and liquidity management increased working capital and liquidity on our undrawn credit facility, providing the Corporation with increased financial flexibility. High Arctic also continued to actively manage its corporate cost structure, with reduced corporate headcount and G&A declining as a percentage of revenue. Finally, while the Corporation did not complete an acquisition during the first nine months of 2026, we continue to actively pursue opportunities in Canada that have the potential to drive shareholder value.

Q3 2026 Highlights

  • Strong operational results driven by higher activity levels were achieved from the rental services segment as revenue increased 60% year over in the quarter,
  • Operating income of $788 in the quarter increased 630% over Q3 2025 result as margin and activity increased profitability and the resultant operating income,
  • G&A expenses declined significantly as a percentage of revenue with the growing scope and scale of equipment and service capabilities,
  • Positive net income contribution from Team Snubbing representing five successive quarters of positive earnings as business development has meaningfully advanced, and
  • Improved working capital position and liquidity position in the quarter to $5.7 and $5.1 million respectively.

Third Quarter 2026 Summary

  • Revenue of $4,676 was achieved for Q3 2026, an increase of $1,746 or 60% compared to Q3 2025. The increase in revenue over Q3 2025 is a result of High Arctic planning for and matching its customer’s busy completion schedule in the quarter.
  • High Arctic generated oilfield services operating margin of $2,219 for Q3 2026 with a corresponding operating margin percentage of 48.8% compared to $1,541 and 54.4% for the prior year comparative quarter. Operating margin was impacted by higher revenues as noted, offset by the reduction in operating margin percentage which was primarily driven by a higher level of modestly lower margin well stimulation services. Well stimulation services typically involve a higher labour component which are at times contracted through a third-party.
  • Adjusted EBITDA for Q3 2026 was $1,429, or 31% of revenue, compared to the prior year comparative quarter of $757 and 26% of revenue. Adjusted EBITDA was primarily impacted by the same factors impacting oilfield services operating margin as noted above.
  • Operating income was $788 in the current year quarter compared to $108 in Q3 2025. The increase in operating income is attributable to the same factors impacting oilfield services operating margins.
  • Net income was $1,034 in Q3 2026 compared to $931 in Q3 2025. This increase in net income was impacted by the same factors impacting oilfield services operating margin as noted above partially offset with reduced income contribution from Team Snubbing as their Q3 2026 financial performance was muted due to cost pressures incurred on multiple start-up activities in the quarter.
  • The Corporation maintained operational excellence and safety throughout the quarter as evidenced by the continuation of lost time incident free work.
  • High Arctic exited Q3 2026 with an increased net working capital position of $5,694, including $3,063 of cash and cash equivalents, an undrawn credit facility and $2,872 in long-term debt.

YTD-2026 Summary

  • YTD revenue of $10,352 increased by $2,696 or 35% compared to YTD-2025. Consistent with the Q3 2026 results, the increase in revenue is attributable to increased customer activity levels and a stable pricing environment for our rental service offerings.
  • High Arctic generated oilfield services operating margin of $4,643 for YTD-2026 with a corresponding operating margin percentage of 46.5% compared to $3,854 and 52.4% for the prior year comparative period. Operating margin was impacted by higher revenues as noted above, offset by the reduction in operating margin percentage which was driven by a higher concentration of slightly lower margin well stimulation services combined with increased equipment repairs and maintenance expenses incurred in Q1 2026.
  • Adjusted EBITDA for YTD-2026 was $2,321, or 22% of revenue, compared to the prior year comparative period of $1,743 and 23% of revenue. The YTD-2026 increase in adjusted EBITDA was a result of the same factors impacting oilfield services operating margin.
  • Operating income for YTD-2026 was $457 compared to a loss of $274 for YTD-2025. This increase in operating income is also attributable to the same factors impacting oilfield services operating margin, as noted above.
  • Net income was $1,892 for YTD-2026 compared to $516 for YTD-2025. This $1,376 increase was driven by the same factors impacting oilfield services operating margin, Team Snubbing’s stronger YTD-2026 performance, gains realized on equipment disposals partially offset by the gain recorded in YTD-2025 on the fair value adjustment on the contingent consideration payable to pursuant to the 2023 Delta acquisition.
  • During the first nine months of 2026, working capital has increased $2,050 while long-term debt has decreased by $131.

Select Comparative Financial Information

The following is a summary of select financial information of the Corporation:

  Three months ended September 30,   Nine months ended
September 30,
 
(thousands of Canadian Dollars, except per share amounts) 2026   2025   2026   2025  
Results from operations:        
Revenue 4,676   2,930   10,352   7,656  
Net income 1,034   931   1,892   516  
Per share (basic & diluted) (1) (3) 0.08   0.07   0.15   0.04  
Oilfield services operating margin (2) 2,219   1,541   4,643   3,854  
Oilfield services operating margin as a % of revenue (2) 48.8 % 54.4 % 46.5 % 52.4 %
EBITDA (2) 1,655   1,545   3,697   2,343  
Per share (basic & diluted) (1) (3) 0.13   0.12   0.29   0.19  
Adjusted EBITDA (2) 1,429   757   2,321   1,743  
Per share (basic & diluted) (1) (3) 0.11   0.06   0.18   0.14  
Operating income (loss) (2) 788   108   457   (274 )
Per share (basic & diluted) (1) (3) 0.06   0.01   0.04   (0.02 )
Cash flow from operations:        
Cash flow from operating activities 336   551   1,355   958  
Per share (basic & diluted) (1) (3) 0.03   0.04   0.11   0.08  
Funds flow from operating activities (2) 1,407   744   2,242   1,549  
Per share (basic & diluted) (1) (3) 0.11   0.06   0.18   0.12  
Capital expenditures 583   173   1,901   966  
     
(thousands of Canadian Dollars, except per share amounts and
common shares outstanding)
    September 30,
2026
  December 31,
2025
 
Financial position:        
Working capital (2)     5,694   3,644  
Cash and cash equivalents     3,063   3,294  
Total assets     31,346   29,883  
Long-term debt (non-current)     2,872   3,003  
Shareholders’ equity     24,141   22,043  
Per share (basic & diluted) (4)     1.90   1.74  
Common shares outstanding – basic (4)     12,696,959   12,696,959  
Common shares outstanding – diluted (4)     12,706,437   12,696,959  


(1) 
The weighted average number of common shares used in calculating both basic and diluted net income per share, EBITDA (Earnings before interest, tax, depreciation and amortization) per share, Adjusted EBITDA per share, operating income (loss) per share, cash flow from operating activities per share, and funds flow from operating activities per share is detailed in Note 14(b) of the Financial Statements.

(2) Readers are cautioned that oilfield services operating margin, oilfield services operating margin as percentage of revenue, EBITDA (earnings before interest, tax, depreciation, and amortization), adjusted EBITDA, operating income (loss), funds flow from operating activities and working capital do not have standardized meanings prescribed by IFRS. See “Non-IFRS Measures” for additional details on the calculations of these measures.

(3) The number of weighted average common shares used in per share basic and diluted calculations for the three months ended September 30, 2026, was 12,696,959 and 12,732,972 and for the three months ended September 30, 2025, was 12,696,959. The number of weighted average common shares used in per share basic and diluted calculations for the nine months ended September 30, 2026, was 12,696,959 and 12,706,437 and for the nine months ended September 30, 2025, was 12,638,634. For periods when the Corporation incurs a net loss or equivalent negative measure, certain potentially dilutive instruments were excluded from the calculation of diluted per share metrics as the inclusion would be anti-dilutive.

(4) Shareholders’ equity per share calculated based on common shares outstanding as at the relevant date.

     
Operating Results
Rental Services Segment
     
  Three months ended
September 30,
  Nine months ended
September 30,
 
(thousands of Canadian Dollars, unless otherwise noted) 2026   2025   2026   2025  
Revenue 4,549   2,832   9,979   7,362  
Oilfield services expenses (2,330 ) (1,291 ) (5,336 ) (3,508 )
Oilfield services operating margin (1) 2,219   1,541   4,643   3,854  
Operating margin (%) (1) 48.8 % 54.4 % 46.5 % 52.4 %

(1) See “Non-IFRS Measures”

The rental services segment consists of High Arctic’s oilfield rental equipment and labour services in Canada, centered upon pressure control equipment and equipment supporting the high-pressure stimulation of oil and gas wells in the WCSB.

Revenue for Q3 2026 of $4,549 was $1,717 or 61% higher than the prior year comparative quarter. Revenue for the nine months ended September 30, 2026, of $9,979 was $2,617 or 36% higher than the prior year comparative period. The increase in revenue experienced for both Q3 2026 and YTD-2026, versus the comparable periods in 2025, was driven primarily by stronger customer activity levels experienced throughout 2026 as High Arctic realized a record number of customer well completions performed for both Q3 2026 and YTD-2026.

Oilfield services operating margin for Q3 2026 of 48.8% was lower than the 54.4% realized in Q3 2025. Operating margin in Q3 2026 was negatively impacted by higher level of activity of well stimulation services when compared to Q3 2025. Well stimulation services typically involve a higher labour component which are at times contracted through a third-party. Additionally, High Arctic realized a modest increase in utilization of third-party rental services in the current year quarter as compared to the prior year quarter. This change in sales mix with more well stimulation services activity, a higher utilization of third-party rental equipment and higher repairs and maintenance related expenses incurred in Q1 2026 negatively impacted the YTD-2026 operating margin when compared to YTD-2025 operating margin.

Other Rental Services Items
During Q1 2026, the Corporation recognized a gain of $340 related to assets disposed of pursuant to a rent-to-own agreement. Additional details related to this transaction are fully described later in this MD&A.

Investments and Corporate Segment
The investments and corporate segment contain all other assets and activity of the Corporation, namely, High Arctic’s equity investment in Team Snubbing, its equity investment in the Seh’ Chene Well Servicing Partnership (“Seh’ Chene Partnership”), industrial property in Clairmont, Alberta, head office functional support, and monetary investments and borrowings. Select analysis and discussion of these results follows by major heading. Readers are advised to reference Note 20, Segmented Information, in the Corporation’s Financial Statements.

Clairmont Industrial Property
Revenue attributable to the Corporation’s industrial property in Clairmont, Alberta, was $127 for Q3 2026 compared to $98 in the prior year comparative quarter (YTD-2026 revenue of $373 compared to revenue of $294 for YTD-2025). The change in revenue is due largely to the reclassification of the reimbursement of property taxes from the lessee as a component of revenue in Q4 2025; previously, the reimbursement was included as a reduction of the underlying operating expense. Gross lease revenue was positively impacted by inflation escalators that are provided for under the lease agreement.

Team Snubbing Equity Investment
The Corporation accounts for the results of its 42% interest in Team Snubbing using the equity method of accounting. The Corporation’s proportionate share of Team Snubbing’s net income for Q3 2026 was $202 compared to a $756 in Q3 2025 (YTD-2026 net income of $1,019 compared to net income of $420 for YTD-2025). Team Snubbing realized revenues for Q3 2026 of $12,075 compared to $9,985 for the prior year comparative quarter and YTD-2026 revenue of $33,364 compared to revenue of $23,974 for YTD-2025, an increase of 21% and 39% respectively. See Note 9 in the Corporation’s Financial Statements for additional details.

In 2026 Team Snubbing has realized improved activity levels and profitability when compared to 2025 year-to-date results. The improvements in revenue for Q3 2026 and both revenue and net income for YTD-2026 are attributable to improved customer activity in Team Snubbing’s operations in Alaska, US combined with the addition of a new application for its services in Canada, focused more heavily on oil production. Activity levels in the US operations were favourably impacted by steady customer demand in the quarter with continued work on the Alaskan North Slope, well workovers performed in various parts of Alaska combined with plug and abandonment work in southern Alaska that concluded in early Q2 2026. Canadian snubbing activity levels have been comparable to what was witnessed in 2025 driven primarily by persistently low AECO natural gas pricing. In Q3 2026 Team incurred some one-time start-up costs for new operations in preparation for coming awards in both Canada and Alaska which was one of the main reasons for the decline in profitability when compared to Q3 2025. As a result of the improved YTD-2026 financial and operational performance, Team Snubbing has made meaningful debt repayments to its primary lender in 2026 and has continued to improve its working capital position quarter over quarter.

Liquidity and Capital Resources

  Three months ended
September 30,
  Nine months ended
September 30,
 
(thousands of Canadian Dollars) 2026 2025   2026   2025  
Cash provided by (used in) operations:        
Operating activities 336   551   1,355   958  
Investing activities (161 ) 215   (1,194 ) (602 )
Financing activities (138 ) (143 ) (408 ) (418 )
Effect of exchange rate changes on cash 1   1   16   (9 )
Increase (decrease) in cash 38   624   (231 ) (71 )

(thousands of Canadian Dollars, unless otherwise noted)     As at
September 30, 2026
As at
December 31, 2025
Current assets     9,421 7,662
Working capital(1)     5,694 3,644
Working capital ratio(1)     2.5:1 1.9:1
Cash and cash equivalents     3,063 3,294

(1) See “Non-IFRS Measures”

Operating Activities
Cash generated from operating activities for Q3 2026 was $336, compared to $551 from operating activities in Q3 2025. Funds from operating activities totaled $1,407 in Q3 2026 compared to $744 for Q3 2025 (see “Non-IFRS Measures”). In Q3 2026, changes in non-cash operating working capital totaled an outflow of $1,071 compared to an outflow of $193 in Q3 2025.

For YTD-2026, cash from operating activities was $1,355 compared to $958 for YTD-2025. Funds flow from operating activities totaled $2,242 for YTD-2026 compared to $1,549 for YTD-2025 (see “Non-IFRS Measures”). For YTD-2026, changes in non-cash operating working capital totaled an outflow of $887 compared to an outflow of $591 for YTD-2025.

Changes in cash from operating activities and funds flow from operating activities for Q3 2026 compared to Q3 2025, and for YTD-2026 compared to YTD-2025, were largely the result of improved financial results for Q3 2026 compared to Q3 2025 combined with the impact of changes in non-cash working capital (as noted above).

Investing Activities
During Q3 2026, the Corporation’s net cash used in investing activities totaled $161 compared to an inflow of $215 for the prior year comparative quarter (YTD-2026 outflow of $1,194 compared to an outflow of $602 for YTD-2025). In the third quarter of 2026 the Corporation made additional strategic growth capital expenditures to enable the growth that was achieved in its rental services segment. Offsetting investing cash outflows was the receipt of payments on notes and other receivables and proceeds received on the disposition of assets.

The change in cash flows from investing activities for Q3 2026 compared to the prior year comparative quarter is due to increased property and equipment expenditures partially offset with the increased payments received related to notes and other receivables. The change in cash flows from investing activities for YTD-2026 compared to the prior year comparative period is due to increased property and equipment expenditures, an increased payment on the contingent consideration obligation relating to the Delta acquisition, partially offset with the increased payments received related to notes and other receivables.

Financing Activities
During Q3 2026, the Corporation’s net cash used in financing activities of $138 was consistent with the prior year comparative quarter of $143. For YTD-2026, net cash used in financing activities of $408 was comparable to $418 for YTD-2025. Cash flows related to financing activities consist of the normal course payments and receipts on the Corporation’s lease liabilities and long-term debt.

Working Capital
As at September 30, 2026, the Corporation’s working capital balance was $5,694 compared to $3,644 as at December 31, 2025. This increase of over two million dollars in working capital was driven by positive EBITDA generated during YTD-2026 combined with the addition of the Team Snubbing 2026 receivable pursuant to the rent-to-own agreement and the sale of the Corporation’s US snubbing assets.

Long-term Debt

(thousands of Canadian Dollars)     As at
September 30, 2026
As at
December 31, 2025
Current     175 175
Non-current     2,872 3,003
Total     3,047 3,178

The Corporation has mortgage financing secured by lands and buildings owned by High Arctic located within Alberta, Canada. The mortgage has a remaining initial term of under three months with a fixed interest rate of 4.30% with payments occurring monthly. The mortgage financing contains certain non-financial covenants requiring lenders’ consent, including changes to the underlying business. As at September 30, 2026 and December 31, 2025, the Corporation was compliant with all covenants associated with the mortgage financing.

Non-IFRS Measures

This Press Release contains references to certain financial measures that do not have a standardized meaning prescribed by IFRS and may not be comparable to the same or similar measures used by other companies. High Arctic uses these financial measures to assess performance and believes these measures provide useful supplemental information to shareholders and investors. These financial measures are computed on a consistent basis for each reporting period and include EBITDA (Earnings before interest, tax, depreciation and amortization), Adjusted EBITDA, oilfield services operating margin and margin percentage, operating income (loss), funds flow from operating activities and working capital. These do not have standardized meanings.

These financial measures should not be considered as an alternative to, or more meaningful than, net income (loss), cash from operating activities, current assets or current liabilities, cash and/or other measures of financial performance as determined in accordance with IFRS.

For additional information regarding non-IFRS measures, including their use to management and investors and reconciliations to measures recognized by IFRS, please refer to the Corporation’s MD&A, which is available online at www.sedar.com and through High Arctic’s website at www.haes.ca.

Forward-Looking Statements
This Press Release contains forward-looking statements. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “seek”, “propose”, “estimate”, “expect”, and similar expressions are intended to identify forward-looking statements. Such statements reflect the Corporation’s current views with respect to future events and are subject to certain risks, uncertainties, and assumptions. Many factors could cause the Corporation’s actual results, performance, or achievements to vary from those described in this Press Release.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying forward-looking statements prove incorrect, actual results may vary materially from those described in this Press Release as intended, planned, anticipated, believed, estimated or expected. Specific forward-looking statements in this Press Release include, among others, statements pertaining to the following: the outlook for the energy industry inclusive of commodity prices, producer activity levels (inclusive of drilling and completions activity) and general energy supply and demand fundamentals that may impact the energy industry as a whole and more specifically as it relates to the Corporation’s customers in Western Canada and Alaska, United States; expectations related to current and future LNG export projects and the impact, if any, on future pricing; and on long-term fundamentals for the upstream energy services sector; the impact, if any, of geo-political events, changes in government, changes to tariffs or related trade policies and the potential impact on the Corporation’s ability to execute its 2026 strategic objectives; fluctuations in interest rates and commodity prices; expectations regarding the Corporation’s ability to manage its liquidity risk, raise capital and manage its debt finance agreements; expectations regarding the impact, if any, of foreign currency exchange rate changes; the nature and the timing of the settlement of future contingent consideration payments; projections of market prices and costs; factors upon which the Corporation will decide whether or not to undertake a specific course of operational action or expansion; the Corporation’s ongoing relationship with its major customers; the Corporation’s ability to seek and execute accretive acquisitions including the timing thereof and the potential operational and financial benefits; management of general and administrative expenses; the maintenance of a strong balance sheet and related financial flexibility; the performance of the Corporation’s investment in Team Snubbing; operational and financial performance of the Corporation’s Canadian rental equipment business in 2026; the Corporation’s expectations for customer activity levels for 2026; scaling the Corporation’s Canadian business; execution on one or more acquisitions of other corporate transactions; and estimated credit risks.

With respect to forward-looking statements contained in this Press Release, the Corporation has made assumptions regarding, among other things, its ability to: maintain its ongoing relationship with major customers; successfully market its services to current and new customers; devise methods for, and achieve its primary objectives; source and obtain equipment from suppliers; successfully manage, operate, and thrive in an environment which is facing much uncertainty; remain competitive in all its operations; attract and retain skilled employees; obtain equity and debt financing on satisfactory terms and manage its liquidity risk.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: economic and financial conditions, including volatility in commodity prices; volatility in interest and exchange rates and capital markets; the level of demand and financial performance of the energy industry; changes in customer demand; and developments and changes in laws and regulations, including in the energy industry.

The Corporation’s actual results could differ materially from those anticipated in these forward-looking statements as a result of the risk factors set forth above and elsewhere in this Press Release, along with the risk factors set out in the most recent Annual Information Form filed on SEDAR+ at www.sedarplus.ca.

The forward-looking statements contained in this Press Release are expressly qualified in their entirety by this cautionary statement. These statements are given only as of the date of this Press Release. The Corporation does not assume any obligation to update these forward-looking statements to reflect new information, subsequent events or otherwise, except as required by law.

About High Arctic Energy Services

High Arctic is an energy services provider. High Arctic provides pressure control equipment and equipment supporting the high-pressure stimulation of oil and gas wells and other oilfield equipment ‎on a rental basis to exploration and production companies, from its bases in Whitecourt and Red Deer, Alberta‎. Additionally, High Arctic maintains a minority equity interest in Team Snubbing, a leading provider of well-control services to the oil and gas drilling industry with operations in Western Canada and Alaska, United States.

For further information contact:

Lonn Bate
Interim Chief Executive Officer
P: 587-318-2218
P: +1 (800) 688 7143 

High Arctic Energy Services Inc.
Suite 2350, 330 – 5th Ave SW
Calgary, Alberta, Canada T2P 0L4
website: www.haes.ca 
Email: info@haes.ca

– Ended third quarter with $24.1 million in cash and restricted cash

– Expects positive fourth quarter earnings between $0.01 and $0.04 per share

TARPON SPRINGS, Fla., November 13, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—
today reported financial results for the third quarter ended September 30, 2026, and provided an update on its clinical and business activities.

Third Quarter 2026 Financial Highlights

  • Cash Position: As of September 30, 2026, Allarity had $24.1 million in cash and restricted cash, including $10.0 million in restricted cash.
  • R&D Expenses: Research and Development expenses were $4.2 million, compared with $1.2 million in the third quarter of 2025. The increase primarily reflected a $3.2 million charge for manufacturing stenoparib active pharmaceutical ingredient (API) to support drug supply for a potential Phase 3 trial.
  • G&A Expenses: General and administrative expenses for the third quarter of 2026 were $1.3 million, unchanged from $1.3 million for the third quarter of 2025.
  • Net Loss: Net loss attributable to common stockholders for the third quarter of 2026 was $6.2 million, compared to $2.8 million for the third quarter of 2025. A $3.2 million one-time manufacturing expense accounted for most of the year-over-year increase.

Fourth Quarter and Full Year 2026 Guidance

  • Liability Settlement Agreement: Subsequent to quarter-end, Allarity entered into a Settlement and Release Agreement with Novartis Pharma AG relating to liabilities arising from the previously terminated dovitinib license agreement. Under the agreement, Allarity paid $1.0 million in full settlement of an aggregate liability of $4.9 million, plus accrued interest.
  • Fourth Quarter and Full Year 2026 Guidance: Allarity is providing guidance for earnings of $0.01 to $0.04 per share in the fourth quarter. The one-time extraordinary gain from extinguishment of debt is expected to exceed operating expenses for the quarter. Allarity anticipates a full year 2026 loss between $0.73 and $0.76 per share. These figures are preliminary and unaudited, and actual results may differ from these estimates. The Company is not providing financial guidance for 2027.

“Completing API manufacturing gives us a head start on drug supply for a potential Phase 3 trial of stenoparib in advanced ovarian cancer while enrollment continues in our Phase 2 studies,” said Thomas Jensen, Chief Executive Officer of Allarity. “We resolved a significant legacy liability and the expected gain from that settlement is the primary driver of our fourth-quarter earnings guidance. Our first contract under the CLIA laboratory services strategy is an early step toward generating revenue from capabilities we built for our own development programs. We’re also strengthening the intellectual property behind those programs, with a newly granted Japanese patent that protects our stenoparib DRP® companion diagnostic into 2039.”

Clinical and Drug Development Progress

  • Phase 2 Ovarian Cancer Program: Enrollment continued in the Phase 2 trial evaluating stenoparib in advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer under U.S. Food and Drug Administration (FDA) Fast Track designation.
  • VA-funded Phase 2 Combination Trial: In parallel, the study evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer continued to enroll patients across multiple U.S. Department of Veterans Affairs (VA) medical centers. The combination trial is fully funded by the VA.
  • Japanese Patent for the Stenoparib DRP® Companion Diagnostic: In September, the Japan Patent Office granted a patent for the stenoparib DRP® companion diagnostic, providing protection into 2039. The patent further strengthens the intellectual property supporting stenoparib development with its drug-specific DRP® companion diagnostic.

Corporate and Strategic Developments

  • CLIA Certification: In July, Allarity announced that its laboratory in Hoersholm, Denmark, had obtained a Certificate of Registration under the Clinical Laboratory Improvement Amendments (CLIA). The certification supports in-house DRP® testing for U.S. clinical trials, including a potential registrational stenoparib trial in advanced ovarian cancer, and enables Allarity to offer laboratory services to other biotechnology and pharmaceutical companies.
  • First Contract Under the CLIA Laboratory Services Strategy: Subsequent to quarter-end, in October, Allarity announced its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy. Under the agreement, the Company will provide a European biotechnology company with development, validation and related laboratory services to support implementation of a proprietary precision oncology predictive device for use in the United States.
  • Expanded Research Capabilities: Allarity expanded its in-house laboratory capabilities to include proteomics and cell line research, complementing its existing gene-expression and DRP® services. The expanded capabilities support further investigation of stenoparib’s mechanism of action and broaden the research services available to external partners.

“Our priority is to build the clinical evidence that will guide the next stage of stenoparib development,” Mr. Jensen concluded. “As we advance that work, we’re focused on delivering for our first CLIA services customer and building a laboratory business that can generate revenue alongside our clinical programs.”

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.

About Stenoparib/2X-121

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Tankyrases have emerged as potential therapeutic targets in cancer due in part to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, including drug-resistant cancers. Through its inhibition of PARP and the WNT signaling pathway, stenoparib has the potential to provide therapeutic benefit across multiple cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer.

Allarity has secured exclusive global rights to develop and commercialize stenoparib, which was originally developed by Eisai Co., Ltd. and was formerly known as E7449 and 2X-121.

Allarity has completed its first Phase 2 trial evaluating stenoparib in patients with advanced ovarian cancer. The trial demonstrated promising and durable clinical benefit in patients with ovarian cancer who received two or more prior lines of therapy and were treated with stenoparib twice daily. Updated data from the trial were presented at the AACR Special Conference on Advances in Ovarian Cancer in September 2025. These analyses remain subject to change as the study data mature. Based on the emerging clinical experience with stenoparib, Allarity developed a new protocol focused on patients with platinum-resistant ovarian cancer, which began enrolling patients in the summer of 2025. The study initially enrolled platinum-resistant or platinum-ineligible patients and has since expanded eligibility to include patients with primary platinum-refractory disease and patients whose disease is clinically evaluable but not measurable by standard RECIST criteria. The additional patient populations will be assessed separately from the original cohort. The study is designed to advance the clinical development of stenoparib toward potential FDA approval.

In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for patients with relapsed small cell lung cancer, or SCLC, began enrolling in early 2026 and is currently enrolling patients at multiple U.S. Department of Veterans Affairs sites.

About the Drug Response Predictor – DRP® Companion Diagnostic

Allarity uses its drug-specific DRP® technology to identify patients who, based on the gene expression signature of their cancer, may be more likely to benefit from a particular drug. By screening patients before treatment, and selecting those with a sufficiently high, drug-specific DRP score, the DRP technology is designed to increase the likelihood of therapeutic benefit.

The DRP methodology is based on the comparisons of sensitive and resistant human cancer cell lines, and incorporates transcriptomic data, clinical tumor biology filters and prior clinical trial outcomes. The DRP uses messenger RNA expression profiles derived from patient biopsies to generate drug-specific predictive scores. The DRP® platform has demonstrated the ability to provide statistically significant predictions of clinical outcome following drug treatment across dozens of retrospective and prospective clinical studies. The platform is designed for potential application across multiple cancer types, is patented for dozens of anti-cancer drugs and has been extensively described in peer-reviewed scientific literature.

Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements reflect current expectations or forecasts regarding future events. The words “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the enrollment, conduct and potential results of the Company’s clinical trials; the potential benefits of expanded study eligibility and DRP®-guided patient selection; the development and potential regulatory approval of stenoparib; the availability of drug supply for potential pivotal development; the Company’s financial guidance for the fourth quarter and full year 2026, including the expected accounting impact of the settlement and extinguishment of debt; the potential benefits and commercial opportunities associated with the Company’s CLIA-certified laboratory and expanded research capabilities; potential recurring laboratory service revenues; the scope and duration of patent protection. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to patient enrollment, trial execution, clinical outcomes and regulatory review; the predictive accuracy and clinical utility of the stenoparib DRP® companion diagnostic; manufacturing quality and drug supply; the possibility that the accounting treatment or financial impact of the settlement may differ from current expectations, and that actual operating expenses, earnings per share or other financial results may differ from the Company’s guidance; maintenance of laboratory certifications and approvals; successful completion of development and validation services and conversion into recurring commercial testing; the scope, validity and enforceability of intellectual property rights; market conditions and the completion of proposed financing transactions; and the Company’s operating costs, debt obligations, liquidity and ability to obtain additional financing. For a discussion of risks and uncertainties and other important factors that could cause actual results to differ materially from those contained in the forward-looking statements, see the risk factors and other disclosures in Allarity’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings are available through the SEC’s website. All information in this press release is as of the date of the release, and the Company undertakes no obligation to update or revise this information, except as required by applicable law.

###

Company Contact:
         investorrelations@allarity.com

ALLARITY THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except for share and per share data)

    September 30,     December 31,  
    2026     2025  
      (Unaudited)          
ASSETS                
Current assets                
Cash   $ 14,092     $ 14,687  
Restricted Cash     9,998       —  
Other current assets     74       265  
Derivative Asset     8       —  
Prepaid expenses     987       2,110  
Tax credit receivable     1,707       866  
Total current assets     26,866       17,928  
Non-current assets:                
Property, plant and equipment, net     354       330  
Total assets   $ 27,220     $ 18,258  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
Current liabilities                
Accounts payable   $ 4,284     $ 4,282  
Accrued expenses and other current liabilities     2,099       2,667  
Income taxes payable     80       81  
Promissory note, net of discounts and accrued interest     21,584       —  
Convertible promissory notes and accrued interest     1,435       1,400  
Total current liabilities     29,482       8,430  
                 
Total liabilities     29,482       8,430  
                 
Commitments and contingencies (Note 9)                
                 
Stockholders’ equity                
Common stock, $0.0001 par value (250,000,000 shares authorized); 19,363,667 and 19,030,619 shares issued and 16,150,028 and 16,080,980 outstanding at September 30, 2026 and December 31, 2025, respectively     3       3  
Additional paid-in capital     145,099       144,233  
Accumulated other comprehensive loss     (1,360 )     (1,021 )
Accumulated deficit     (142,552 )     (130,197 )
Treasury stock, at cost; 3,213,639 and 2,949,639 shares at September 30, 2026, and December 31, 2025, respectively     (3,452 )     (3,190 )
Total stockholders’ equity (deficit)     (2,262 )     9,828  
Total liabilities and stockholders’ equity   $ 27,220     $ 18,258  

ALLARITY THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(in thousands, except for share and per share data)

    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2026     2025     2026     2025  
Revenue:                                
License Revenue   $ 5     $ —     $ 30     $ —  
Total revenue     5       —       30       —  
                                 
Operating expenses:                                
Research and development     4,219       1,203       6,861       4,927  
General and administrative     1,293       1,315       4,035       4,760  
Total operating expenses     5,512       2,518       10,896       9,687  
Loss from operations     (5,507 )     (2,518 )     (10,866 )     (9,687 )
Other income (expense):                                
Interest income     205       187       585       646  
Interest expense     (1,012 )     (57 )     (1,960 )     (126 )
Foreign exchange gain (loss)     (22 )     (418 )     (122 )     1,308  
Change in fair value of derivative and warrant liabilities     136       —       8       1  
Total other income (expense), net     (693 )     (288 )     (1,489 )     1,829  
                                 
Net loss   $ (6,200 )   $ (2,806 )   $ (12,355 )   $ (7,858 )
                                 
Net loss per common share, basic and diluted   $ (0.39 )   $ (0.19 )   $ (0.77 )   $ (0.57 )
Weighted average common shares outstanding, basic and diluted     15,937,567       14,739,800       15,942,556       13,849,976  
                                 
Other comprehensive loss                                
Net loss   $ (6,200 )   $ (2,806 )   $ (12,355 )   $ (7,858 )
Change in cumulative translation adjustment     (14 )     158       (339 )     (1,949 )
Total comprehensive loss   $ (6,214 )   $ (2,648 )   $ (12,694 )   $ (9,807 )

Attachment

Chips&Media Integrates High-Performance Video Codec IP into Next-Gen AI Semiconductors for Physical AI & Robotics in Partnership with Mobilint

•Mobilint Begins Mass Production of Next-Generation Chips Powered by Chips&Media Video IP… Targeting Humanoid and Robot Markets•Securing Core Infrastructure for Next-Generation Robotics by Meeting 8K 60fps High-Efficiency Multi-Stream Requirements and ISO 26262 ASIL-B Functional Safety•Partnership to Expand Across the Entire Multimedia Spectrum, Beyond Video Codecs to Frame Buffer and Data Compression IPs
•Mobilint Begins Mass Production of Next-Generation Chips Powered by Chips&Media Video IP… Targeting Humanoid and Robot Markets•Securing Core Infrastructure for Next-Generation Robotics by Meeting 8K 60fps High-Efficiency Multi-Stream Requirements and ISO 26262 ASIL-B Functional Safety•Partnership to Expand Across the Entire Multimedia Spectrum, Beyond Video Codecs to Frame Buffer and Data Compression IPs
  • Mobilint Begins Mass Production of Next-Generation Chips Powered by Chips&Media Video IP… Targeting Humanoid and Robot Markets
  • Securing Core Infrastructure for Next-Generation Robotics by Meeting 8K 60fps High-Efficiency Multi-Stream Requirements and ISO 26262 ASIL-B Functional Safety
  • Partnership to Expand Across the Entire Multimedia Spectrum, Beyond Video Codecs to Frame Buffer and Data Compression IPs

SEOUL, South Korea, Nov. 13, 2026 (GLOBE NEWSWIRE) — Chips&Media (CEO Sang-hyun Kim, KOSDAQ: 094360), a global leader in video IP (Intellectual Property), announced today that it is successfully expanding its business into the “Physical AI and Robotics” market through a partnership with Mobilint (CEO Dong-joo Shin), an edge AI semiconductor innovator, accompanying the mass production of Mobilint’s next-generation chips powered by Chips&Media’s high-performance video codec IP.

Mobilint has built a close technical partnership by licensing Chips&Media’s H.264/AVC, H.265/HEVC and AV1 codecs several years ago and built upon this foundation by additional license including AV2, H.266/VVC to their portfolio recently to broaden their technical scope. Through this collaboration, both companies are entering mass production for Mobilint’s high-performance chips, accelerating their penetration into the rapidly growing global robotics and humanoid markets. Notably, Mobilint’s flagship AI semiconductor, ‘Regulus,’ was recently deployed on the Naro space launch vehicle and successfully validated its performance in outer space, further elevating industry expectations for this robotics market entry.

Successful chip implementation in the Physical AI and robotics fields requires satisfying stringent criteria: High Throughput, Low Latency, and Safety & Stability. Chips&Media’s VPU (Video Processing Unit) was selected as it perfectly meets these market demands.

Typically, chips for robots must simultaneously process 8 to 20 multi-channel cameras. Chips&Media’s VPU delivers industry-leading performance of 8K at 60fps with a single core, efficiently processing multi-stream encoding without latency. Furthermore, future industrial and home humanoids targeted by Mobilint require strict automotive-grade functional safety, for which Chips&Media’s ISO 26262 ASIL-B certification served as the decisive selection factor. This is the result of synergy between Chips&Media’s high-performance, low-power know-how accumulated across numerous edge device markets such as mobile and computing, and its safety certification capabilities prepared specifically for the automotive market.

Regarding this mass production milestone, Mobilint CEO Dong-joo Shin stated, “It is meaningful to present a solution optimized for the robotics and Physical AI market through the combination of Mobilint’s innovative AI semiconductor technology and Chips&Media’s proven high-performance video IP. Through this collaboration, we aim to deliver differentiated value to customers in the next-generation robotics market, including humanoids.”

Chips&Media CEO Sang-hyun Kim emphasized, “We are thrilled that our long-standing partnership with Mobilint has led to the valuable achievement of actual chip mass production and entry into the robotics market. Building on our proven technological leadership in the edge AI and automotive sectors, we will lead the Physical AI era together with Mobilint.”

Meanwhile, building upon the success of this video codec collaboration, both companies plan to continuously expand their cooperative scope across the broader multimedia domain, including Frame Buffer Compression (FBC) IP and Data Compression IP.

About Mobilint
Founded in 2019 and headquartered in Seoul, Korea, Mobilint is a fabless AI semiconductor company specializing in high-performance, energy-efficient NPUs and AI SoCs for edge and on-device AI applications. The company owns proprietary NPU IP and AI SoC design technologies, with proven deployments across smart city, healthcare, autonomous driving, security, industrial AI, and mobile AI device applications. Learn more: www.mobilint.com.

About Chips&Media Inc.
Chips&Media is a multimedia IP leader offering HW video codec IP, image processing NPU, lossless/lossy frame buffer compression IP & others. Since 2003, Chips&Media has exclusively focused on the HW video codec IP industry. It has powered over 3,000,000,000 units in the market, adopted by more than 150 semiconductor companies. Chips&Media’s video codec IP supports all major and legacy formats from 1080p up to 8K 120fps, including HEVC/H.265, AVC/H.264, AV1, AV2, VP9, APV, VVC/H.266, JPEG & others.

The recent introduction of our image processing NPU IP is transforming Chips&Media into a premium multimedia IP provider. It is custom NPU designed to work for imaging applications at high-quality and high-resolution in edge devices.

For more information, please visit our website at www.chipsnmedia.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/76bf4b3b-73e0-4428-bf91-ae0d35145802

CONTACT: eniel.lee@chipsnmedia.com

WOBURN, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended September 30, 2026.

Third Quarter 2026 Highlights

  • Net product revenue of $9.1 million, an increase of 29.8% compared to $7.0 million in the prior-year period.
  • Gross margin of 74.4%, compared to 70.7% in the prior-year period, an improvement of approximately 370 basis points, reflecting the lower Ameluz® cost structure established following the closing of the strategic transaction with Biofrontera AG in October 2025 (the “Strategic Transaction”), partially offset by ITC Matter-related inventory write-downs and higher lamp and device costs.
  • Net loss of $6.4 million, or $(0.42) per share, compared to a net loss of $6.6 million, or $(0.62) per share, in the prior-year period.
  • Adjusted EBITDA of $(5.5) million, compared to $(6.0) million in the prior-year period.
  • On September 9, 2026 FDA Approval of Ameluz on September for the treatment of Superficial Basal Cell Carcinoma (sBCC), making Ameluz plus Red-Light the first and only PDT approved for the treatment of cancerous skin tumors.
  • US Customs and Border Protection ruled that the re-designed XL-C lamp did not violate the ITC order and could be imported for use in the US market.

Nine Months Ended September 30, 2026 Highlights

  • Net product revenue of $31.2 million, an increase of 26.6% from $24.6 million in the prior-year period.
  • Gross margin of 78.0%, compared to 67.7% in the prior-year period.
  • Net loss of $11.8 million, or $(0.89) per share, compared to a net loss of $16.2 million, or $(1.67) per share, in the prior-year period.
  • Adjusted EBITDA of $(9.3) million, compared to $(15.5) million in the prior-year period.

Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera, stated: “The third quarter was a pivotal one for Biofrontera. On September 9, the FDA approved Ameluz® PDT for the treatment of superficial basal cell carcinoma (sBCC), making it the first PDT approved in the United States for a cancerous skin tumor. Five days later, U.S. Customs and Border Protection ruled that our redesigned RhodoLED® XL-C is not subject to the ITC exclusion order, which allows us to again serve the customers who rely on our large-field lamp. Revenue grew 30% in the quarter and 27% for the first nine months, and our gross margin continues to reflect the lower cost structure we put in place with the Strategic Transaction. The quarter also carried the legal and remediation costs of the ITC Matter, and with the XL-C now cleared our attention is on execution. We are preparing to begin commercializing Ameluz® for sBCC later in the fourth quarter and into the first quarter of 2027, and in October we submitted a supplemental New Drug Application to expand the Ameluz® label for actinic keratosis to the extremities, neck and trunk. Each of these indications is served by the lamps and the sales force we already have in place.”

Third Quarter 2026 Financial Results

Net product revenue for the third quarter of 2026 was $9.1 million, an increase of $2.1 million, or 29.8%, from $7.0 million in the third quarter of 2025. The increase was primarily attributable to a 23.3% increase in Ameluz® unit volume resulting in an increase of $1.6 million and $0.3 million due to price and mix increase, with the balance reflecting higher device sales. The increase in unit volume was partially driven by accelerated order timing from certain customers in early July 2026 in anticipation of potential supply restrictions resulting from the limited exclusion order and cease and desist order issued by the U.S. International Trade Commission (“ITC”) related to our RhodoLED® XL lamp, which took effect on July 6, 2026 (the “ITC Matter”) and importantly, commercial execution where we have focused on increasing utilization with key accounts and bringing Ameluz to new dermatology customers. We believe that the accelerated ordering impacted the timing of orders rather than total demand. On September 14, 2026, U.S. Customs and Border Protection (“CBP”) issued a ruling finding that our redesigned RhodoLED® XL-C is not subject to the exclusion order, and we began placing XL-C lamps during the 3rd quarter, enabling these customers to again purchase Ameluz®.

Cost of revenues was $2.3 million, compared to $2.0 million in the prior-year period, producing gross profit of $6.7 million and a gross margin of 74.4%, compared to gross profit of $4.9 million and a gross margin of 70.7% in the third quarter of 2025. The improvement was driven principally by the transition from the prior transfer pricing arrangement to a cost structure comprising Ameluz® direct cost plus a 12% earnout on net revenue, which reduced cost of Ameluz® despite a 23.3% increase in unit volume. This was partially offset by a $0.4 million increase in lamp and device costs, including $0.3 million of ITC Matter-related inventory write-downs.

Selling, general and administrative (“SG&A”) expenses, including SG&A, related party, were $12.5 million, compared to $10.4 million in the prior-year quarter, an increase of $2.1 million, driven primarily by a $0.9 million increase in legal fees related to the ITC Matter, $0.7 million of combined costs from lamp manufacturing and regulatory and product affairs, and a $0.5 million increase in direct sales expenses, mainly commissions on higher Ameluz® sales volume.

Research and development expenses were $0.5 million, compared to $0.9 million in the prior-year quarter, reflecting the substantial completion of clinical trials.

Patent remediation expense related to the ITC Matter was $0.3 million, compared to none in the prior-year quarter, reflecting a $0.2 million increase in the estimated remediation cost following the September 14, 2026 CBP ruling and a $0.1 million write-down of loaner and RhodoLED® XL lamps used in the remediation program.

Net loss for the third quarter was $6.4 million, or $(0.42) per share, compared to a net loss of $6.6 million, or $(0.62) per share, for the prior-year quarter. Adjusted EBITDA, a non-GAAP measure reconciled below, was $(5.5) million, compared to $(6.0) million in the prior-year period.

Nine Months Ended September 30, 2026 Financial Results

Net product revenue for the nine months ended September 30, 2026 was $31.2 million, an increase of $6.6 million, or 26.6%, from $24.6 million in the first nine months of 2025. The increase reflects Ameluz® unit volume growth of $5.5 million and a price impact of approximately $0.7 million and the remainder generally attributable to increases in device sales.

Cost of revenues was $6.8 million, compared to $8.0 million in the prior-year period, producing gross profit of $24.3 million and gross margin of 78.0%, compared to gross profit of $16.7 million and gross margin of 67.7% in the prior-year period. The improvement was driven principally by the same transition in Ameluz® cost structure described above.

SG&A expenses, including SG&A related party, were $33.2 million, compared to $29.6 million in the prior-year period, an increase of $3.5 million. The increase was primarily driven by $1.8 million of combined costs from manufacturing and regulatory and product affairs; $1.2 million of higher direct sales expenses, mainly sales commissions reflecting Ameluz® sales volume growth; and $0.8 million of higher sales support expenses, reflecting increased commercial activity. Other SG&A expenses, including stock-based compensation, depreciation and amortization, and bad debt, increased $0.3 million. These increases were partially offset by a $0.3 million decrease in selling, general and administrative expenses, related party, and a $0.2 million decrease in general and administrative costs.

Research and development expenses were $1.8 million, compared to $2.9 million, reflecting the substantial completion of clinical trials.

Patent remediation expense related to the ITC Matter was $0.7 million, compared to none in the prior-year period. Including inventory write-downs recorded in cost of revenues, the Company has recognized total charges of $1.1 million related to the ITC Matter through September 30, 2026, consisting of $0.6 million of accrued remediation costs and $0.5 million of inventory write-downs to net realizable value. Of the accrued remediation costs, $0.2 million was settled with inventory used in the remediation program and the remaining $0.4 million is paid or payable in cash.

Net loss was $11.8 million, or $(0.89) per share, compared to a net loss of $16.2 million, or $(1.67) per share, in the prior-year period. Adjusted EBITDA was $(9.3) million, compared to $(15.5) million in the prior-year period.

Please refer to the table below which presents a GAAP to non-GAAP reconciliation of Adjusted EBITDA for the third quarters and first nine months of 2026 and 2025.

Balance Sheet and Cash Flow

Cash and cash equivalents were $3.2 million as of September 30, 2026, compared to $6.4 million as of December 31, 2025. Cash used in operating activities for the nine months ended September 30, 2026 was $3.2 million, compared to $11.0 million in the prior-year period.

Total liabilities were $21.7 million as of September 30, 2026, compared to $18.1 million at December 31, 2025. The Company’s outstanding indebtedness as of September 30, 2026 consisted of $4.7 million of convertible notes, net, maturing in November 2027. The Company has no bank or other term debt.

Conference Call

Biofrontera will host a conference call and webcast on Friday, November 13, 2026 at 10:00 a.m., Eastern Time. Participants may dial 1-877-877-1275 (U.S./Canada toll-free), 1-866-605-3852 (Canada toll-free), or 1-412-858-5202 (international).

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with photodynamic therapy (PDT). The Company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, and, following FDA approval in September 2026, superficial basal cell carcinoma, and are in development for additional indications. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.

Use of Non-GAAP Financial Measures

We define adjusted EBITDA as net income or loss before interest income and expense, income taxes, depreciation and amortization, and other non-operating items from our statements of operations as well as certain other items considered outside the normal course of our operations specifically described below. Adjusted EBITDA is not a presentation made in accordance with GAAP. Our definition of adjusted EBITDA may vary from the use of similarly titled measures by others in our industry due to the potential inconsistencies in the method of calculation and differences due to items subject to interpretation. Adjusted EBITDA should not be considered as an alternative to net income or loss, operating income/(loss), cash flows from operating activities or any other performance measures derived in accordance with GAAP as measures of operating performance or liquidity. Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP.

We exclude the change in fair value of warrant liabilities and the change in fair value of investment, related party, because these items are non-cash. We exclude patent remediation expense and ITC-related inventory write-downs because they relate to a discrete adverse legal and regulatory matter that is not indicative of the Company’s ongoing operating performance. We exclude stock-based compensation, which is non-cash, because the subjective assumptions and variety of award types involved can cause this expense to vary significantly, and its exclusion allows for more meaningful comparisons of our operating results to peer companies.

Adjusted EBITDA margin is Adjusted EBITDA for a particular period expressed as a percentage of revenues for that period. We use Adjusted EBITDA to measure our performance from period to period and to compare our results to those of our competitors, and we believe that, when viewed with GAAP financial information, this presentation provides investors with useful information regarding financial and business trends related to our results of operations and a more meaningful understanding of our ongoing operating performance.

Investor Contact
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, in this press release, including statements regarding our strategy, future operations, regulatory process, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. The words “believe”, “anticipate”, “intend”, “expect”, “target”, “goal”, “estimate”, “plan”, “assume”, “may”, “will”, “predict”, “project”, “would”, “could” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You should read this press release and any documents referenced herein completely and with the understanding that our actual future results may be materially different from what we expect. While we have based these forward-looking statements on our current expectations and projections about future events, we may not actually achieve the plans, intentions or expectations disclosed in or implied by our forward-looking statements, and you should not place undue reliance on our forward-looking statements.

These forward-looking statements are subject to risks, uncertainties and assumptions about us and accordingly, actual results or events could differ materially from the plans, intentions and expectations disclosed in or implied by the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our ability to achieve and sustain profitability; our ability to compete effectively in selling our products; our ability to expand, manage and maintain our direct sales and marketing efforts, including our ability to obtain the financing to develop our marketing strategy, if needed; changes in our relationship with our manufacturing partners and the possible impact of tariffs; our ability to manufacture our products; our ability to adequately protect our intellectual property and operate the business without infringing upon the intellectual property rights of others; our actual financial results may vary significantly from forecasts and from period to period; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; market risks regarding consolidation and group purchasing organizations (“GPOs”) in the healthcare industry; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third-party payors for our products, or procedures using our products significantly declines; our ability to market, commercialize, achieve market acceptance for and sell our products; the fact that product quality issues or product defects may harm our business; any claims brought against the Company, including but not limited to product liability claims, claims of patent infringement, or claims challenging the validity of our intellectual property; our ability to maintain compliance with The Nasdaq Stock Market, LLC continued listing standards; our ability to comply with the requirements of being a public company; the progress, timing and completion of research, development and preclinical studies and clinical trials for our products; our ability to obtain and maintain the regulatory approvals necessary for the marketing of our products in the United States; and other factors that may be disclosed in the Company’s filings with the Securities and Exchange Commission (“SEC”), which can be obtained on the SEC website at www.sec.gov. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.

BIOFRONTERA INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value and share amounts)

    September 30,
2026
    December 31,
2025
 
      (Unaudited)          
ASSETS                
Current assets:                
Cash and cash equivalents   $ 3,218     $ 6,392  
Investment, related party     12       9  
Accounts receivable, net     4,787       7,291  
Inventories     1,733       1,426  
Prepaid expenses and other current assets     1,111       2,279  
Other assets, related party     242       686  
                 
Total current assets     11,103       18,083  
                 
Inventories, long term     2,565       3,729  
Property and equipment, net     2,112       2,158  
Operating lease right-of-use assets     2,707       1,584  
Intangible assets, net     2,528       2,650  
Other assets     451       360  
                 
Total assets   $ 21,466     $ 28,564  
                 
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY                
Current liabilities:                
Accounts payable     6,896       1,855  
Accounts payable, related parties, net     731       4,811  
                 
Operating lease liabilities     463       332  
Accrued expenses and other current liabilities     6,147       4,897  
                 
Total current liabilities     14,237       11,895  
                 
Long-term liabilities:                
Convertible notes payable, net     4,749       4,589  
Warrant liabilities     395       351  
Operating lease liabilities, non-current     2,322       1,240  
Other liabilities     6       9  
                 
Total liabilities     21,709       18,084  
                 
Commitments and contingencies                
                 
Stockholders’ (deficit) equity:                
Convertible Preferred Stock, $0.001 par value, 20,000,000 shares authorized; 759 and 2,050 Series B-2; 6,498 and 6,593 Series B-3; 8,390 and 10,719 Series C; and 3,019 and 3,019 Series D shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     –       –  
Common stock, $0.001 par value, 70,000,000 shares authorized; 17,949,000 and 11,648,323 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     18       12  
Additional paid-in capital     139,463       138,413  
Accumulated deficit     (139,724 )     (127,945 )
                 
Total stockholders’ (deficit) equity     (243 )     10,480  
                 
Total liabilities and stockholders’ (deficit) equity   $ 21,466     $ 28,564  


BIOFRONTERA INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts and number of shares)
(Unaudited)

    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
                         
Product revenues, net   $ 9,070     $ 6,988     $ 31,157     $ 24,605  
                                 
Operating expenses                                
Cost of revenues, related party     2,164       1,922       6,180       7,377  
Cost of revenues, other     157       123       667       578  
                                 
Selling, general and administrative     12,461       10,047       33,083       29,229  
Selling, general and administrative, related party     29       320       72       396  
Patent remediation expense     306       –       698       –  
Research and development     450       854       1,798       2,932  
                                 
Total operating expenses     15,567       13,266       42,498       40,512  
                                 
Loss from operations     (6,497 )     (6,278 )     (11,341 )     (15,907 )
                                 
Other income (expense)                                
Change in fair value of warrant liabilities     132       (285 )     (44 )     417  
Change in fair value of investment, related party     4       1       4       3  
Interest expense, net     (128 )     (111 )     (379 )     (331 )
Other income (expense), net     70       30       8       (333 )
                                 
Total other income (expense)     78       (365 )     (411 )     (244 )
                                 
Loss before income taxes     (6,419 )     (6,643 )     (11,752 )     (16,151 )
Income tax expense     4       6       27       25  
                                 
Net loss   $ (6,423 )   $ (6,649 )   $ (11,779 )   $ (16,176 )
                                 
Loss per common share:                                
Basic and diluted   $ (0.42 )   $ (0.62 )   $ (0.89 )   $ (1.67 )
                                 
Weighted-average common shares outstanding:                                
Basic and diluted     15,280,526       10,776,739       13,309,031       9,674,378  


BIOFRONTERA INC.

GAAP TO NON-GAAP ADJUSTED EBITDA RECONCILIATION
(In thousands, except per share amounts and number of shares)
(Unaudited)

    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Net loss   $ (6,423 )   $ (6,649 )   $ (11,779 )   $ (16,176 )
Interest expense, net     128       111       379       331  
Income tax expense     4       6       27       25  
Depreciation and amortization     59       25       179       76  
EBITDA     (6,232 )     (6,507 )     (11,194 )     (15,744 )
Change in fair value of warrant liabilities     (132 )     285       44       (417 )
Change in fair value of investment, related party     (4 )     (1 )     (4 )     (3 )
ITC-related inventory write-downs     317       –       375       –  
Patent remediation expense     306       –       698       –  
Stock-based compensation     224       236       829       662 (1)
Adjusted EBITDA   $ (5,521 )   $ (5,987 )   $ (9,252 )   $ (15,502 )
Adjusted EBITDA margin     -60.9 %     -85.7 %     -29.7 %     -63.0 %


(1)
Stock-based compensation for the nine months ended September 30, 2025 included in the Adjusted EBITDA reconciliation above has been revised from $0.4 million, as previously reported, to $0.7 million to correct the amount presented in the prior-period reconciliation. The revision affects only this non-GAAP measure and had no effect on the Company’s condensed consolidated financial statements.

NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) — SoFi Securities LLC, a leading provider of thematic and income ETFs, today announced monthly distributions on the SoFi Social 50 Income ETF (SFYI).

Distribution as of 11/12/2026

ETF
Ticker
Distribution
per Share
Distribution
Rate *
30-Day
SEC Yield**
Ex-Date Record
Date
Payment
Date
SFYI $0.47454 2.00% -0.02% 11/13/2026 11/13/2026 11/16/2026
             

Inception date: 7/6/2026
Click here to view standardized performance for SFYI.

SFYI, launched in partnership with Tidal Investments LLC, seeks current income and long-term capital appreciation.

About SoFi
SoFi Technologies (NASDAQ: SOFI) is the everything app for digital financial services on a mission to help people achieve financial independence to realize their ambitions. 15.8 million members trust SoFi to borrow, save, spend, invest, and protect their money and buy, sell and hold their crypto – all in one app – and get access to financial planners, exclusive experiences, and a thriving community. Banks, fintechs, and brands use innovative capabilities from SoFi Tech Solutions to serve over 134 million global accounts. For more information, visit www.sofi.com or download our iOS and Android apps.
©2026 SoFi Technologies, Inc. All rights reserved.

About Tidal Investments LLC 
Formed by ETF industry pioneers and thought leaders, Tidal Investments LLC sets out to revolutionize the way ETFs have historically been developed, launched, marketed, and sold. With a focus on growing AUM, Tidal offers a comprehensive suite of services, proprietary tools, and methodologies designed to bring lasting ideas to market. Tidal is an advocate for ETF innovation. The firm is on a mission to provide issuers with the intelligence and tools needed to efficiently and to effectively launch ETFs and to optimize growth potential in a highly competitive space. For more information, visit https://www.tidalfinancialgroup.com/.  

Performance is historical and does not guarantee future results. Current performance may be lower or higher than quoted. Investment returns and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Performance data for the most recent month-end is available above. Returns less than one year are cumulative. Shares of any ETF are bought and sold at market price (not NAV) and may trade at a discount or premium to NAV. Shares are not individually redeemable from the Fund and may be only be acquired or redeemed from the fund in creation units. Brokerage commissions will reduce returns. Short term performance, in particular, is not a good indication of the fund’s future performance, and an investment should not be made based solely on returns.

* The distribution may include a combination of ordinary dividends, capital gain, and return of investor capital and has the potential to change during any given tax year. Please refer to the 19a-1 Notice, which can be located on the Fund’s website, regarding the composition of distributions, including return of capital. Final determination of a distribution’s tax character will be made on Form 1099 DIV. Distributions are not guaranteed.

** The 30-Day SEC Yield represents net investment income, which excludes option income, earned by such ETF over the 30-Day period ended October 31, 2026, expressed as an annual percentage rate based on such ETF’s share price at the end of the 30-Day period.

The Distribution Rate and 30-Day SEC Yield is not indicative of future distributions, if any, on the ETFs. In particular, future distributions on any ETF may differ significantly from its Distribution Rate or 30-Day SEC Yield. You are not guaranteed a distribution under the ETFs. Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero. Accordingly, the Distribution Rate and 30-Day SEC Yield will change over time, and such change may be significant. The distribution may include a combination of ordinary dividends, capital gain, and return of investor capital, which may decrease a fund’s NAV and trading price over time. As a result, an investor may suffer significant losses to their investment. These distribution rates caused by unusually favorable market conditions may not be sustainable. Such conditions may not continue to exist and there should be no expectation that this performance may be repeated in the future. Additional fund risks can be found below.

Please read the prospectus carefully before you invest. Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus. This material must be preceded or accompanied by a prospectus. A prospectus may be obtained by clicking here.

Investing involves risk. Principal loss is possible.

ETFs have their own management fees that reduce returns. SoFi Invest and/or its affiliates earn management fees from SoFi proprietary ETFs. SoFi Invest does not receive sales commissions from ETFs it invests in on your behalf. Review the prospectus for fees, expenses, and objectives. Fees may change at any time.

Derivatives Risk. Derivatives are financial instruments that derive value from the underlying reference asset or assets, such as stocks, bonds, or funds (including ETFs), interest rates or indexes.

Distribution Risk. The Fund intends to make cash distributions on a monthly basis. There is no assurance that the Fund will make a distribution in any given month.

REIT Risk. Through its indirect investments in REITs, the Fund is subject to the risks of investing in the real estate market, including decreases in property revenues, increases in interest rates, increases in property taxes and operating expenses, legal and regulatory changes, a lack of credit or capital, defaults by borrowers or tenants, environmental problems and natural disasters.

Concentration Risk. The Fund’s investments will be concentrated in an industry or group of industries to the extent SFYF is so concentrated.

High Portfolio Turnover Risk. The Fund may actively and frequently trade all or a significant portion of the Fund’s holdings. A high portfolio turnover rate increases transaction costs, which may increase the Fund’s expenses.

Non-Diversification Risk. The Fund is classified as “non-diversified,” which means the Fund may invest a larger percentage of its assets in the securities of a smaller number of issuers than a diversified fund. Investment in a limited number of issuers exposes the Fund to greater market risk and potential losses than if its assets were diversified among a greater number of issuers.

New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors do not have a track record or history on which to base their investment decisions.

SoFi ETFs are distributed by Foreside Fund Services, LLC.

CONTACT: Contact: pr@sofi.com

Total net revenue increased approximately 9% to $19.2 million for the third quarter of 2026 compared to the third quarter of 2025

Fortress repaid its credit facility in full in September 2026

A subsidiary of Fortress entered into a license agreement for FB-607, which is currently being evaluated in a randomized, double-blind, placebo-controlled Phase 2 study to assess the safety and efficacy in patients with irritable bowel syndrome with diarrhea

Partnered programs continue to advance, with Crystalys Therapeutics closing a $130 million Series B financing, and royalties generated from ZYCUBO® and UNLOXCYT™

MIAMI, Nov. 13, 2026 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2026.

Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “The third quarter of 2026 reflected continued execution across our diversified portfolio. In September, we repaid in full our credit facility with Oaktree and we also recently announced the in-licensing of FB-607, a novel combination therapy to treat the symptoms of irritable bowel syndrome with diarrhea (“IBS-D”). FB-607 is currently being studied in a randomized, placebo-controlled, Phase 2 trial for IBS-D and we expect to release top-line data in the second half of 2027. Journey Medical continues to build momentum with Emrosi®, with approximately 40,000 in total prescriptions for the third quarter of 2026, supported by continued improvement in the mix of prescriptions reimbursed by health plans. Additionally, in September, anselamimab (formerly CAEL-101) was approved in Japan for the treatment of systemic kappa light chain amyloidosis. With our growing royalty income from ZYCUBO® and UNLOXCYT™, and multiple potential catalysts across our partnered programs, we believe Fortress is well positioned to continue driving long-term value for our shareholders.”

Recent Corporate Highlights1:

Corporate Updates

  • Fortress Repays Oaktree Credit Facility in Full. In September 2026, Fortress repaid in full the remaining $15.0 million in outstanding principal under its senior secured credit agreement with Oaktree Fund Administration, LLC (the “Oaktree Agreement”). Upon repayment, all indebtedness under the Oaktree Agreement was satisfied and paid in full, all liens and other security interests in Fortress’ property securing the facility were released and terminated, and the Oaktree Agreement terminated in accordance with its terms. Fortress originally entered into the $50.0 million credit facility in July 2024. Following the repayment, Fortress has no outstanding debt at the parent level.
  • Fortress Subsidiary Licenses FB-607 for IBS-D. In the third quarter of 2026, a majority-owned and controlled private subsidiary of Fortress entered into an exclusive licensing agreement with Cedars-Sinai to develop FB-607, a novel drug with the potential to improve care for patients with IBS-D. FB-607 is currently being evaluated in a multi-center, randomized, double-blind, placebo-controlled Phase 2 study to assess the safety and efficacy in patients with IBS-D.

Commercial Portfolio Updates

  • Journey Medical Continues to Grow Emrosi®. At the end of March 2025, our partner company Journey Medical Corporation (“Journey Medical”) commercially launched Emrosi® (40mg Minocycline Hydrochloride Modified-Release Capsules, consisting of 10mg immediate release and 30mg extended release pellets), also known as DFD-29, for inflammatory lesions of rosacea. Emrosi® was approved by the FDA in November 2024 and is available by prescription at specialty pharmacy chains. Journey Medical reported that Emrosi® had generated approximately 40,000 prescriptions in the third quarter of 2026. Journey Medical reported net product revenues of $18.9 million for the third quarter of 2026, compared to net product revenues of $17.0 million for the third quarter ended September 30, 2025.
  • Royalties. In the third quarter of 2026, Cyprium Therapeutics, Inc. (“Cyprium”) recognized $0.2 million in royalty revenue on net sales of ZYCUBO®, and Fortress recognized $0.1 million in royalty income (contingent consideration) on net sales of UNLOXCYT™.

Clinical Updates

  • Crystalys Raises $130M Series B. In July 2026, Crystalys Therapeutics (“Crystalys”) announced a $130 million Series B financing to support the late-stage global clinical development and commercialization preparation for dotinurad. Patients continue to be enrolled in Crystalys’ two randomized, double-blind, multicenter global Phase 3 trials, RUBY and TOPAZ, evaluating dotinurad, a next-generation, once daily oral URAT1 inhibitor with potential for best-in-class safety and efficacy for the treatment of gout, as well as its Phase 2 AMETHYST study in difficult-to-treat gout. Our controlled subsidiary Urica is an equity holder of Crystalys and eligible to receive a 3% royalty on future net sales of dotinurad.
  • Anselamimab Receives Approval in Japan. In September 2026, anselamimab (formerly known as CAEL-101) was approved in Japan for the treatment of systemic kappa light chain amyloidosis. Through the sale of Caelum Biosciences, Fortress is eligible to receive commercial milestone payments based on sales and a regulatory milestone payment upon approval by the FDA.
  • Other Portfolio Programs Continue to Advance with Potential Upcoming Data and Trial Initiations. Triplex is currently in multiple ongoing clinical trials for cytomegalovirus (CMV) treatment and prevention in solid organ and stem cell transplants, combination trials with CAR T cell therapies for hematologic malignancies. We are exploring the possibility of initiating a clinical trial evaluating MB-109, a combination CAR T cell therapy and oncolytic virus, in the first quarter of 2027 for patients with IL13Rα2-positive recurrent glioblastoma and high-grade astrocytoma.

Financial Results:

  • As of September 30, 2026, Fortress’ consolidated cash and cash equivalents totaled $152.2 million, compared to $79.4 million as of December 31, 2025, an increase of $72.8 million year-to-date.
  • Fortress’ consolidated cash and cash equivalents totaling $152.2 million as of September 30, 2026 includes $114.1 million attributable to Fortress and the private subsidiaries, $1.5 million attributable to Avenue Therapeutics, $14.3 million attributable to Mustang Bio and $22.3 million attributable to Journey Medical.
    • Fortress’ consolidated cash and cash equivalents totaled $79.4 million as of December 31, 2025, and includes $35.2 million attributable to Fortress and private subsidiaries, $2.9 million attributable to Avenue Therapeutics, $17.3 million attributable to Mustang Bio and $24.1 million attributable to Journey Medical.
  • Fortress’ consolidated net revenue totaled $19.2 million for the third quarter ended September 30, 2026, $18.9 million of which was generated from our marketed dermatology products. This compares to consolidated net revenue totaling $17.6 million for the third quarter of 2025, $17.0 million of which was generated from our marketed dermatology products.
  • Consolidated research and development expenses totaled $1.7 million for the third quarter ended September 30, 2026, compared to $0.2 million for the third quarter ended September 30, 2025.
  • Consolidated selling, general and administrative costs were $17.8 million for the third quarter ended September 30, 2026, compared to $17.4 million for the third quarter ended September 30, 2025.
  • Consolidated net loss attributable to common stockholders was $(7.9) million, or $(0.23) per share basic and diluted, for the third quarter ended September 30, 2026, compared to net income attributable to common stockholders of $3.7 million, or $0.13 per share basic, and $0.11 per share diluted, for the third quarter ended September 30, 2025.

About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Institute and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.

Forward-Looking Statements
Statements in this press release that are not descriptions of historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology are generally intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include risks relating to: our growth strategy, financing and strategic agreements and relationships; our need for substantial additional funds and uncertainties relating to financings; uncertainty related to the timing and amounts expected to be realized from future milestone, contingent value right, royalty or similar future revenue streams, if at all; our ability to identify, acquire, close and integrate product candidates successfully and on a timely basis; our ability to attract, integrate and retain key personnel; the early stage of product candidates under development; the results of research and development activities; uncertainties relating to preclinical and clinical testing; our ability to obtain regulatory approval for products under development; our ability to successfully commercialize products for which we receive regulatory approval or receive royalties or other distributions from third parties; our ability to secure and maintain third-party manufacturing, marketing and distribution of our and our partner companies’ products and product candidates; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.

Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com

FORTRESS BIOTECH, INC. AND SUBSIDIARIES
Unaudited Condensed Consolidated Balance Sheets
($ in thousands except for share and per share amounts)
 
  September 30,
2026
  December 31,
2025
 
ASSETS            
Current assets            
Cash and cash equivalents $ 152,186     $ 79,381    
Accounts receivable, net   47,387       29,783    
Inventory   7,772       9,624    
Other receivables – related party   54       158    
Prepaid expenses and other current assets   2,964       4,895    
Total current assets   210,363       123,841    
             
Property and equipment, net   2,320       2,519    
Operating lease right-of-use asset, net   11,028       12,302    
Restricted cash   1,220       1,220    
Equity investments, at fair value   29,452       17,660    
Intangible assets, net   24,541       27,605    
Other assets   1,291       401    
Total assets $ 280,215     $ 185,548    
             
LIABILITIES AND STOCKHOLDERS’ EQUITY            
Current liabilities            
Accounts payable and accrued expenses $ 56,628     $ 47,125    
Income taxes payable   5,119       356    
Common stock warrant liabilities   —       1    
Operating lease liabilities, short-term   2,513       2,127    
Partner company notes payable, short-term   7,500       —    
Other current liabilities   —       135    
Total current liabilities   71,760       49,744    
             
Notes payable, long-term, net   18,077       52,417    
Operating lease liabilities, long-term   10,861       12,672    
Partner company redeemable perpetual preferred liability   —       7,085    
Other long-term liabilities   2,496       1,447    
Total liabilities   103,194       123,365    
             
Commitments and contingencies            
             
Stockholders’ equity            
Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized,
5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of
September 30, 2026 and December 31, 2025, respectively, liquidation value of $25.00 per share
  3       3    
Common stock, $0.001 par value, 200,000,000 shares authorized, 33,490,362 and 31,364,094
shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively
  33       31    
Additional paid-in-capital   789,953       783,891    
Accumulated deficit   (629,992 )     (734,052 )  
Total stockholders’ equity attributed to the Company   159,997       49,873    
             
Non-controlling interests   17,024       12,310    
Total stockholders’ equity   177,021       62,183    
Total liabilities and stockholders’ equity $ 280,215     $ 185,548    
                 

FORTRESS BIOTECH, INC. AND SUBSIDIARIES
Unaudited CondensedConsolidated Statements of Operations
($ in thousands except for share and per share amounts)
 
  Three Months Ended September 30,   Nine Months Ended September 30,  
  2026   2025   2026   2025  
Revenue                        
Product revenue, net $ 18,925     $ 17,025     $ 52,685     $ 45,173    
Other revenue   234       606       1,229       2,010    
Net revenue   19,159       17,631       53,914       47,183    
                         
Operating expenses                        
Cost of goods – (excluding amortization of acquired
intangible assets)
  5,884       5,755       18,245       15,484    
Amortization of acquired intangible assets   969       1,064       3,064       3,193    
Research and development   1,678       208       3,023       12,268    
Selling, general and administrative   17,821       17,415       54,519       81,670    
Total operating expenses   26,352       24,442       78,851       112,615    
Loss from operations   (7,193 )     (6,811 )     (24,937 )     (65,432 )  
                         
Other income (expense)                        
Interest income   1,295       736       3,446       1,848    
Interest expense and financing fee   (2,498 )     (2,742 )     (7,342 )     (8,065 )  
Gain on sale of priority review voucher, net of
expenses
  —       —       158,873       —    
Change in fair value of partner company derivative
liability
  —       —       (7,085 )     —    
Loss on common stock warrant liabilities   —       (2 )     1       (399 )  
Gain from deconsolidation of subsidiary   104       —       186       27,127    
Other income (expense)   (18 )     17,672       11,764       17,599    
Total other income (expense)   (1,117 )     15,664       159,843       38,110    
Income (loss) before income tax expense   (8,310 )     8,853       134,906       (27,322 )  
                         
Income tax (benefit) expense   (56 )     26       5,395       196    
Net income (loss)   (8,254 )     8,827       129,511       (27,518 )  
                         
Attributable to non-controlling interests   2,409       (2,977 )     (25,451 )     38,270    
Net income (loss) attributable to Fortress $ (5,845 )   $ 5,850     $ 104,060     $ 10,752    
                         
Preferred A dividends cumulated, and Fortress’ share
of subsidiary deemed dividends
  (2,008 )     (2,174 )     (6,024 )     (6,436 )  
Net income (loss) attributable to common
stockholders
$ (7,853 )   $ 3,675     $ 98,036     $ 4,316    
                         
Net income (loss) per common share attributable to
common stockholders – basic
$ (0.23 )   $ 0.13     $ 2.94     $ 0.16    
Net income (loss) per common share attributable to
common stockholders – diluted
$ (0.23 )   $ 0.11     $ 2.51     $ 0.14    
                         
Weighted average common shares outstanding –
basic
  33,746,832       27,244,474       33,394,537       27,075,216    
Weighted average common shares outstanding –
diluted
  33,746,832       33,100,961       38,997,513       30,695,996    
                                 

                              

1 This press release references products being developed or commercialized by Fortress, by Fortress’ private or public subsidiaries (referred to herein as “subsidiaries” or “partner companies”) and by entities with whom one of the foregoing parties has a significant business relationship, such as an exclusive license or an ongoing product-related payment obligation (such entities referred to herein as “partners”). The words “we”, “us” and “our” may refer to Fortress individually, to one or more of our subsidiaries and/or partner companies, or to all such entities as a group, as dictated by context.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.